Targeted delivery of immune therapeutics to lymph nodes prolongs cardiac allograft survival

Baharak Bahmani, Mayuko Uehara, Liwei Jiang, Farideh Ordikhani, Naima Banouni, Takaharu Ichimura, Zhabiz Solhjou, Georg J. Furtmüller, Gerald Brandacher, David Alvarez, Ulrich H. von Andrian, Kenji Uchimura, Qiaobing Xu, Ishaan Vohra, Osman A. Yilmam, Yousef Haik, Jamil Azzi, Vivek Kasinath, Jonathan S. Bromberg, Martina M. McGrathReza Abdi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The targeted delivery of therapeutic drugs to lymph nodes (LNs) provides an unprecedented opportunity to improve the outcomes of transplantation and immune-mediated diseases. The high endothelial venule is a specialized segment of LN vasculature that uniquely expresses peripheral node addressin (PNAd) molecules. PNAd is recognized by MECA79 mAb. We previously generated a MECA79 mAb-coated microparticle (MP) that carries tacrolimus. Although this MP trafficked to LNs, it demonstrated limited therapeutic efficacy in our transplant model. Here, we have synthesized a nanoparticle (NP) as a carrier of anti-CD3, and optimized the conjugation strategy to coat the NP surface with MECA79 mAb (MECA79-anti-CD3-NP) to enhance LN accumulation. As compared with nonconjugated NPs, a significantly higher quantity of MECA79-NPs accumulated in the draining lymph node (DLN). Many MECA79-NPs underwent internalization by T cells and dendritic cells within the LNs. Short-term treatment of murine cardiac allograft recipients with MECA79-anti-CD3-NP resulted in significantly prolonged allograft survival in comparison with the control groups. Prolonged graft survival following treatment with MECA79-anti-CD3-NP was characterized by a significant increase in intragraft and DLN Treg populations. Treg depletion abrogated the prolongation of heart allograft survival. We believe this targeted approach of drug delivery could redefine the methods of administering immune therapeutics in transplantation.

Original languageEnglish
Pages (from-to)4770-4786
Number of pages17
JournalThe Journal of clinical investigation
Volume128
Issue number11
DOIs
Publication statusPublished - 1 Nov 2018

Fingerprint

Allografts
Lymph Nodes
Nanoparticles
Therapeutics
Transplantation
Venules
Immune System Diseases
Tacrolimus
Graft Survival
Pharmaceutical Preparations
Dendritic Cells
T-Lymphocytes
Transplants
Control Groups
Population

Keywords

  • Immunology
  • Nanotechnology
  • Transplantation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bahmani, B., Uehara, M., Jiang, L., Ordikhani, F., Banouni, N., Ichimura, T., ... Abdi, R. (2018). Targeted delivery of immune therapeutics to lymph nodes prolongs cardiac allograft survival. The Journal of clinical investigation, 128(11), 4770-4786. https://doi.org/10.1172/JCI120923

Targeted delivery of immune therapeutics to lymph nodes prolongs cardiac allograft survival. / Bahmani, Baharak; Uehara, Mayuko; Jiang, Liwei; Ordikhani, Farideh; Banouni, Naima; Ichimura, Takaharu; Solhjou, Zhabiz; Furtmüller, Georg J.; Brandacher, Gerald; Alvarez, David; von Andrian, Ulrich H.; Uchimura, Kenji; Xu, Qiaobing; Vohra, Ishaan; Yilmam, Osman A.; Haik, Yousef; Azzi, Jamil; Kasinath, Vivek; Bromberg, Jonathan S.; McGrath, Martina M.; Abdi, Reza.

In: The Journal of clinical investigation, Vol. 128, No. 11, 01.11.2018, p. 4770-4786.

Research output: Contribution to journalArticle

Bahmani, B, Uehara, M, Jiang, L, Ordikhani, F, Banouni, N, Ichimura, T, Solhjou, Z, Furtmüller, GJ, Brandacher, G, Alvarez, D, von Andrian, UH, Uchimura, K, Xu, Q, Vohra, I, Yilmam, OA, Haik, Y, Azzi, J, Kasinath, V, Bromberg, JS, McGrath, MM & Abdi, R 2018, 'Targeted delivery of immune therapeutics to lymph nodes prolongs cardiac allograft survival', The Journal of clinical investigation, vol. 128, no. 11, pp. 4770-4786. https://doi.org/10.1172/JCI120923
Bahmani, Baharak ; Uehara, Mayuko ; Jiang, Liwei ; Ordikhani, Farideh ; Banouni, Naima ; Ichimura, Takaharu ; Solhjou, Zhabiz ; Furtmüller, Georg J. ; Brandacher, Gerald ; Alvarez, David ; von Andrian, Ulrich H. ; Uchimura, Kenji ; Xu, Qiaobing ; Vohra, Ishaan ; Yilmam, Osman A. ; Haik, Yousef ; Azzi, Jamil ; Kasinath, Vivek ; Bromberg, Jonathan S. ; McGrath, Martina M. ; Abdi, Reza. / Targeted delivery of immune therapeutics to lymph nodes prolongs cardiac allograft survival. In: The Journal of clinical investigation. 2018 ; Vol. 128, No. 11. pp. 4770-4786.
@article{68ac00121fd64bfda8077d37317d35c3,
title = "Targeted delivery of immune therapeutics to lymph nodes prolongs cardiac allograft survival",
abstract = "The targeted delivery of therapeutic drugs to lymph nodes (LNs) provides an unprecedented opportunity to improve the outcomes of transplantation and immune-mediated diseases. The high endothelial venule is a specialized segment of LN vasculature that uniquely expresses peripheral node addressin (PNAd) molecules. PNAd is recognized by MECA79 mAb. We previously generated a MECA79 mAb-coated microparticle (MP) that carries tacrolimus. Although this MP trafficked to LNs, it demonstrated limited therapeutic efficacy in our transplant model. Here, we have synthesized a nanoparticle (NP) as a carrier of anti-CD3, and optimized the conjugation strategy to coat the NP surface with MECA79 mAb (MECA79-anti-CD3-NP) to enhance LN accumulation. As compared with nonconjugated NPs, a significantly higher quantity of MECA79-NPs accumulated in the draining lymph node (DLN). Many MECA79-NPs underwent internalization by T cells and dendritic cells within the LNs. Short-term treatment of murine cardiac allograft recipients with MECA79-anti-CD3-NP resulted in significantly prolonged allograft survival in comparison with the control groups. Prolonged graft survival following treatment with MECA79-anti-CD3-NP was characterized by a significant increase in intragraft and DLN Treg populations. Treg depletion abrogated the prolongation of heart allograft survival. We believe this targeted approach of drug delivery could redefine the methods of administering immune therapeutics in transplantation.",
keywords = "Immunology, Nanotechnology, Transplantation",
author = "Baharak Bahmani and Mayuko Uehara and Liwei Jiang and Farideh Ordikhani and Naima Banouni and Takaharu Ichimura and Zhabiz Solhjou and Furtm{\"u}ller, {Georg J.} and Gerald Brandacher and David Alvarez and {von Andrian}, {Ulrich H.} and Kenji Uchimura and Qiaobing Xu and Ishaan Vohra and Yilmam, {Osman A.} and Yousef Haik and Jamil Azzi and Vivek Kasinath and Bromberg, {Jonathan S.} and McGrath, {Martina M.} and Reza Abdi",
year = "2018",
month = "11",
day = "1",
doi = "10.1172/JCI120923",
language = "English",
volume = "128",
pages = "4770--4786",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "11",

}

TY - JOUR

T1 - Targeted delivery of immune therapeutics to lymph nodes prolongs cardiac allograft survival

AU - Bahmani, Baharak

AU - Uehara, Mayuko

AU - Jiang, Liwei

AU - Ordikhani, Farideh

AU - Banouni, Naima

AU - Ichimura, Takaharu

AU - Solhjou, Zhabiz

AU - Furtmüller, Georg J.

AU - Brandacher, Gerald

AU - Alvarez, David

AU - von Andrian, Ulrich H.

AU - Uchimura, Kenji

AU - Xu, Qiaobing

AU - Vohra, Ishaan

AU - Yilmam, Osman A.

AU - Haik, Yousef

AU - Azzi, Jamil

AU - Kasinath, Vivek

AU - Bromberg, Jonathan S.

AU - McGrath, Martina M.

AU - Abdi, Reza

PY - 2018/11/1

Y1 - 2018/11/1

N2 - The targeted delivery of therapeutic drugs to lymph nodes (LNs) provides an unprecedented opportunity to improve the outcomes of transplantation and immune-mediated diseases. The high endothelial venule is a specialized segment of LN vasculature that uniquely expresses peripheral node addressin (PNAd) molecules. PNAd is recognized by MECA79 mAb. We previously generated a MECA79 mAb-coated microparticle (MP) that carries tacrolimus. Although this MP trafficked to LNs, it demonstrated limited therapeutic efficacy in our transplant model. Here, we have synthesized a nanoparticle (NP) as a carrier of anti-CD3, and optimized the conjugation strategy to coat the NP surface with MECA79 mAb (MECA79-anti-CD3-NP) to enhance LN accumulation. As compared with nonconjugated NPs, a significantly higher quantity of MECA79-NPs accumulated in the draining lymph node (DLN). Many MECA79-NPs underwent internalization by T cells and dendritic cells within the LNs. Short-term treatment of murine cardiac allograft recipients with MECA79-anti-CD3-NP resulted in significantly prolonged allograft survival in comparison with the control groups. Prolonged graft survival following treatment with MECA79-anti-CD3-NP was characterized by a significant increase in intragraft and DLN Treg populations. Treg depletion abrogated the prolongation of heart allograft survival. We believe this targeted approach of drug delivery could redefine the methods of administering immune therapeutics in transplantation.

AB - The targeted delivery of therapeutic drugs to lymph nodes (LNs) provides an unprecedented opportunity to improve the outcomes of transplantation and immune-mediated diseases. The high endothelial venule is a specialized segment of LN vasculature that uniquely expresses peripheral node addressin (PNAd) molecules. PNAd is recognized by MECA79 mAb. We previously generated a MECA79 mAb-coated microparticle (MP) that carries tacrolimus. Although this MP trafficked to LNs, it demonstrated limited therapeutic efficacy in our transplant model. Here, we have synthesized a nanoparticle (NP) as a carrier of anti-CD3, and optimized the conjugation strategy to coat the NP surface with MECA79 mAb (MECA79-anti-CD3-NP) to enhance LN accumulation. As compared with nonconjugated NPs, a significantly higher quantity of MECA79-NPs accumulated in the draining lymph node (DLN). Many MECA79-NPs underwent internalization by T cells and dendritic cells within the LNs. Short-term treatment of murine cardiac allograft recipients with MECA79-anti-CD3-NP resulted in significantly prolonged allograft survival in comparison with the control groups. Prolonged graft survival following treatment with MECA79-anti-CD3-NP was characterized by a significant increase in intragraft and DLN Treg populations. Treg depletion abrogated the prolongation of heart allograft survival. We believe this targeted approach of drug delivery could redefine the methods of administering immune therapeutics in transplantation.

KW - Immunology

KW - Nanotechnology

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=85055824754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055824754&partnerID=8YFLogxK

U2 - 10.1172/JCI120923

DO - 10.1172/JCI120923

M3 - Article

C2 - 30277476

AN - SCOPUS:85055824754

VL - 128

SP - 4770

EP - 4786

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 11

ER -